1 minute 52 secondsDesign-partner direction
From manufacturer to practice adoption
A structured path through market definition, direct or partner channel design, team and training choices, RFPs, launch-tactic comparison, governance, and learning.
Aesthetic medicine commercialization
Commercialize aesthetic products through the practices that adopt, recommend, and use them.
UEM supports smaller and growth-stage manufacturers bringing injectables, professional skincare, and other practice-dispensed aesthetic products into U.S. dermatology, plastic-surgery, medical-office, and med-spa channels.
Discuss an aesthetic launch
Practice adoption · Channel design · Commercial discipline
Dermatology practices
Plastic-surgery practices
Medical offices
Med-spa networks
Manufacturer-to-practice commercialization
See the system before you help us validate it.
The first film explains the complete commercialization path. The second shows how the operating view changes for the people responsible for category strategy, channel design, field execution, education, and practice adoption.
1 minute 46 secondsProposed role lenses
The people behind practice adoption
Proposed decision lenses for executives, brand and channel leaders, regional and district teams, territory and practice-development roles, education, operations, and analytics.
UEM supports aesthetic-medicine commercialization today. The RxLaunchOS sector configuration shown here is exploratory, under validation, and not represented as a generally available or proven product.
Inside the platform
See the operating mechanics being adapted for the practice channel.
These are actual RxLaunchOS screens populated with fictional Asterion pharmaceutical demonstration data. They show the governed operating mechanics being adapted—not a live aesthetic-medicine tenant or a validated sector result.
Actual platform screen
Practice-channel coverage and capacity
The current product connects target universes, geography, workload, capacity, and vacancies. For aesthetic medicine, the same operating mechanic would be configured around practices, providers, and adoption conditions.
Actual platform screen
Channel and operating-model decisions
Direct, distributor, hybrid, and staged routes can be compared without losing the assumptions, trade-offs, evidence, owner, or human approval behind the decision.
Actual platform screen
Training and enablement readiness
Evidence, severity, ownership, and state turn provider education, staff confidence, and practice enablement gaps into visible work instead of disconnected follow-up.
Actual platform screen
A versioned commercialization record
Leadership can review decisions, risks, dependencies, evidence, and supersession history in one governed record while accountable people retain approval authority.
Commercialization capabilities
A practice-based market needs more than consumer marketing.
Success depends on the product, the provider, the practice team, the channel, and the patient experience working as one commercial system. UEM helps leadership make those connections explicit and govern the decisions behind them.
01
Market and channel design
Define the practice segments, account priorities, routes to market, partner roles, and commercial assumptions that should shape the launch.
02
Provider and practice adoption
Connect product positioning with provider education, practice economics, staff confidence, patient experience, and the realities of adoption inside a professional setting.
03
Commercial team and network design
Design the right field, inside, distributor, training, and account-support model for the product, channel, geography, and stage of growth.
04
Launch governance and measurement
Make claims, evidence, owners, dependencies, risks, milestones, and performance signals visible before commercial activity outruns the operating system.
Different jobs, one controlled launch record
Give each role the context, decisions, and next actions needed to do its job.
These proposed role lenses are being tested with manufacturers and experienced practice-channel operators. They change the questions and planning horizon; they do not create access, rank employees, or replace accountable leadership.
Market, model, and investment
GM / commercial executive
Pressure-test category assumptions, channel economics, capability gaps, partner choices, investment gates, and launch risks before capital is committed.
National commercial design
Brand, sales, and channel leaders
Connect positioning, target practice segments, account strategy, coverage, distributor roles, education, measures, and launch sequence.
Coverage and intervention
Regional and district leaders
Compare territory coverage, manager capacity, practice barriers, training needs, partner performance, and evidence-backed resource requests.
Practice adoption plan
Territory and practice-development teams
Turn provider, staff, economics, education, barrier, commitment, and outcome facts into the next purposeful account action.
Readiness and confidence
Clinical education and enablement
Coordinate training readiness, provider and staff education, approved evidence, practice workflows, follow-up, and escalation.
Operating evidence
Commercial operations and analytics
Keep roster, territory, inventory and service assumptions, data quality, partner obligations, adoption signals, and reporting connected.
The operating distinction
The discipline carries over. The market assumptions do not.
UEM brings the same evidence, readiness, organization, channel, and executive decision discipline used in regulated commercialization. Aesthetic medicine, however, has its own provider economics, purchase patterns, training needs, customer experience, and routes to adoption.
We do not copy a pharmaceutical launch template into an aesthetic business. The operating model is designed around the product category, the intended practice setting, the evidence available, and the capabilities the organization can support.
Named-brand affiliations, client outcomes, and clinical claims are never implied without authorization and evidence.
Connected work
ClearSpec Labs
UEM contributes commercialization and operating-model perspective to ClearSpec Labs, a separate Seven16 Group research-commerce initiative built around clearer product information and evidence governance.
ClearSpec Labs' current public catalog is for research use only. It is not a source of products for human or veterinary use.
Visit ClearSpec LabsSystem direction
RxLaunchOS for aesthetic medicine
This work is informing a future aesthetic-medicine configuration of UEM's commercialization operating system: separate sector methodology, shared decision discipline, and no reuse of pharmaceutical assumptions as aesthetic-market facts.
The sector configuration is exploratory and is not represented as a generally available, off-the-shelf product today.
Explore the RxLaunchOS modelStart with the market decision